Franco GCD, Fierro DJ, Cuevas SMT, Gándara AC, Candanedo GF, Domínguez RI

Language: Spanish
References: 20
Page: 100-105
PDF size: 2561.73 Kb.

ABSTRACT

Multiple endocrine neoplasia type 1 is an autosomal dominant hereditary syndrome that leads to the development of endocrine tumors in glands such as the parathyroids, pancreas, and pituitary. Pancreatic neuroendocrine tumors, which are common in this condition, may be functional or nonfunctional and pose diagnostic and therapeutic challenges due to their multifocal and heterogeneous behavior. Management requires an individualized, multidisciplinary approach. We report the case of a 32-year-old woman with multiple endocrine neoplasia type 1 and multiple pancreatic lesions detected incidentally. Imaging studies demonstrated three hypervascular pancreatic tumors with intense somatostatin receptor uptake and variable metabolic activity. The patient underwent distal pancreatectomy and splenectomy. Histopathological analysis confirmed well-differentiated neuroendocrine tumors without lymph node involvement. This case highlights the value of multimodal imaging and multidisciplinary collaboration for the diagnosis, treatment, and follow-up of pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1.

REFERENCES

1. Sadowski SM, Triponez F. Management of pancreatic neuroendocrine tumors in patients with MEN 1. Gland Surg. 2015; 4: 63-68. doi: 10.3978/j.issn.2227-684X.2014.12.01.

2. Brandi ML, Pieterman CRC, English KA, et al. Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice. Lancet Diabetes Endocrinol. 2025; 13: 699-721. doi: 10.1016/S2213-8587(25)00119-6.

3. Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022; 33: 115-154. doi: 10.1007/s12022-022-09708-2.

4. Rupe E, Diab M, Xoubi L, et al. Imaging update of pancreatic neuroendocrine neoplasms. Semin Roentgenol. 2025; 60: 31-43. doi: 10.1053/j.ro.2024.12.001.

5. Rinzivillo M, Partelli S, Prosperi D, et al. Clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced entero-pancreatic neuroendocrine neoplasms. Oncologist. 2018; 23: 186-192. doi: 10.1634/theoncologist.2017-0278.

6. Magi L, Prosperi D, Lamberti G, et al. Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. Endocrine. 2022; 76: 484-490. doi: 10.1007/s12020-022-03000-3.

7. Rajamohan N, Khasawneh H, Singh A, et al. PET/CT and PET/MRI in neuroendocrine neoplasms. Abdom Radiol (NY). 2022; 47: 4058-4072. doi: 10.1007/s00261-022-03516-2.

8. Deng J, Liao X, Cao H. Neuroendocrine tumors in a patient with multiple endocrine neoplasia type 1 syndrome: a case report and review of the literature. Medicine (Baltimore). 2023; 102: e34350. doi: 10.1097/MD.0000000000034350.

9. Mills EA, DeLucia BP, Wayne CD, et al. Functional pancreatic neuroendocrine neoplasms: an overview. Endocrines. 2025; 6: 38. doi: 10.3390/endocrines6030038.

10. Van Beek DJ, Nell S, Pieterman CRC, et al. Prognostic factors and survival in MEN1 patients with gastrinomas: results from the DutchMEN study group (DMSG). J Surg Oncol. 2019; 120: 966-975. doi: 10.1002/jso.25667.

11. Niederle B, Selberherr A, Bartsch DK, et al. Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome - an International Consensus Statement. Neuroendocrinology. 2021; 111: 609-630. doi: 10.1159/000511791.

12. Paiella S, Landoni L, Tebaldi S, et al. Dual-tracer (68Ga-DOTATOC and 18F-FDG) PET/CT scan and G1-G2 nonfunctioning pancreatic neuroendocrine tumors: a single-center retrospective evaluation of 124 nonmetastatic resected cases. Neuroendocrinology. 2022; 112: 143-152. doi: 10.1159/000514809.

13. Machado MC. Surgical treatment of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. Clinics (Sao Paulo). 2012; 67: 145-148. doi: 10.6061/clinics/2012(sup01)24.

14. Sulciner ML, Clancy TE. Surgical management of pancreatic neuroendocrine tumors. Cancers (Basel). 2023; 15: 2006. doi: 10.3390/cancers15072006.

15. Xourafas D, Tavakkoli A, Clancy TE, Ashley SW. Distal pancreatic resection for neuroendocrine tumors: is laparoscopic really better than open? J Gastrointest Surg. 2015; 19: 831-840. doi: 10.1007/s11605-015-2788-1.

16. Zhang L, Ventin M, Arya S, et al. Surgical and oncologic outcomes after pancreatectomy for pancreatic neuroendocrine tumor in multiple endocrine neoplasia type 1 and von Hippel-Lindau syndrome: a large, multi-institutional cohort study. J Am Coll Surg. 2026; 242: 1602-1612. doi: 10.1097/XCS.0000000000001829.

17. Ghabra S, Ramamoorthy B, Andrews SG, Sadowski SM. Surgical management and long-term evaluation of pancreatic neuroendocrine tumors. Surg Clin North Am. 2024; 104: 891-908. doi: 10.1016/j.suc.2024.02.019.

18. Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. ESR essentials: role of PET/CT in neuroendocrine tumors. Eur Radiol. 2025; 35: 1903-1912. doi: 10.1007/s00330-024-11095-7.

19. Chen J, Yang Y, Liu Y, Kan H. Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation. World J Surg Oncol. 2021; 19: 11. doi: 10.1186/s12957-020-02115-z.

20. Gu DY, Fu Q, Xue BY, Kan JB, Bai JA, Tang QY. Comparison of clinical features between sporadic pancreatic neuroendocrine tumors and those associated with MEN1. Zhonghua Yi Xue Za Zhi. 2022; 102: 1014-1019. doi: 10.3760/cma.j.cn112137-20210822-01906.